Log in

NASDAQ:FLXN - Flexion Therapeutics Stock Price, Forecast & News

$17.51
-0.32 (-1.79 %)
(As of 01/19/2020 05:37 AM ET)
Today's Range
$17.35
Now: $17.51
$18.28
50-Day Range
$17.51
MA: $19.42
$21.13
52-Week Range
$8.76
Now: $17.51
$22.98
Volume1.00 million shs
Average Volume1.16 million shs
Market Capitalization$668.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.52 million
Book Value$2.91 per share

Profitability

Net Income$-169,660,000.00
Net Margins-266.51%

Miscellaneous

Employees272
Market Cap$668.36 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.


Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) announced its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.01. The specialty pharmaceutical company earned $21.79 million during the quarter, compared to the consensus estimate of $18.85 million. Flexion Therapeutics had a negative net margin of 266.51% and a negative return on equity of 271.22%. View Flexion Therapeutics' Earnings History.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Flexion Therapeutics.

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics issued an update on its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23.7-23.7 million, compared to the consensus revenue estimate of $24.15 million.

What price target have analysts set for FLXN?

9 equities research analysts have issued 1 year price objectives for Flexion Therapeutics' stock. Their forecasts range from $18.00 to $36.00. On average, they anticipate Flexion Therapeutics' share price to reach $25.88 in the next year. This suggests a possible upside of 47.8% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

What is the consensus analysts' recommendation for Flexion Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

Has Flexion Therapeutics been receiving favorable news coverage?

News articles about FLXN stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Flexion Therapeutics.

Are investors shorting Flexion Therapeutics?

Flexion Therapeutics saw a increase in short interest in December. As of December 13th, there was short interest totalling 7,450,000 shares, an increase of 6.9% from the November 28th total of 6,970,000 shares. Based on an average daily trading volume, of 660,100 shares, the days-to-cover ratio is currently 11.3 days. Approximately 23.4% of the company's shares are short sold. View Flexion Therapeutics' Current Options Chain.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Cara Therapeutics (CARA), Verastem (VSTM), TherapeuticsMD (TXMD), AcelRx Pharmaceuticals (ACRX), Omeros (OMER), Celgene (CELG) and Gilead Sciences (GILD).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
  • Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
  • Scott Young, VP of Corp. Communications & Investor Relations

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.54%) and Campbell Capital Management Inc. (0.04%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Campbell Capital Management Inc.. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $17.51.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $668.36 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  515 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  842
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel